Abstract
Background Gastroesophageal reflux disease (GERDs) is a common chronic digestive system disease, in which the symptoms of reflux esophagitis (RE) seriously affect the quality of life. Aims We aimed to study the therapeutic effect of Zhujie Hewei granules (ZHG) on reflux esophagitis in model rats. Materials and Methods A rat model of RE was established with the steps of half pylorus ligation, cardiotomy, and hydrochloric acid perfusion. The rats in treatment groups were orally administered with 1.30, 2.60, or 5.20 g/kg ZHG once daily for 28 days. Histopathological changes of the esophagus were observed with hematoxylin-eosin staining. The content of total bilirubin and pH in gastric juice was determined. Esophageal mucosal injury was assessed by macroscopic observation scores, mucosal injury index scores, and esophageal inflammation scores. The levels of gastrin (GAS), motilin (MTL), and vasoactive intestinal peptide (VIP) in serum were evaluated by using ELISA kits. Results After treatment with ZHG, the body weight of RE rats tended to increase drastically, the macroscopic observation scores of the esophagus mucous membrane decreased (P < 0.05), the mucosal injury index scores decreased (P < 0.05), the gastric pH values increased (P < 0.05), and the levels of serum MTL and VIP decreased (P < 0.05). In addition, the high dose of the ZHG-treated group showed lower serum GAS (P < 0.05), while the high and middle doses of the ZHG-treated groups showed lower esophageal inflammation scores (P < 0.05). Conclusions ZHG was effective in treating RE in rats due using mechanisms including improving the pH value of gastric contents, decreasing the gastrointestinal hormones (including GAS, MTL, and VIP), and improving the inflammatory damage.
Highlights
Gastroesophageal reflux diseases (GERDs) are the symptoms or complications resulting from the reflux of gastric contents into the esophagus, oral cavity, or lung [1]
GERDs are common clinical chronic diseases that up to 40% of the world’s population suffer from at least once a month [2]. e prevalence of gastroesophageal reflux in Asia is lower than that in Europe and America, whereas there is an increasing trend in Asia in recent years [3]. e reflux of gastric acid, bile salts, and other noxious agents contained in the refluxed gastric juice is regarded as the major cause of reflux esophagitis (RE) [4]
After oral Zhujie Hewei granules (ZHG), the body weight of rats increased, especially in the high dose group; the result shows that the ZHG is beneficial to the treatment of RE rats; the pH value of supernatant of gastric contents in rats increased, which indicated that ZHG had inhibitory effect on gastric acid and acid reflux. e secretion of total bilirubin has no obvious effect, which showed that ZHG will not affect the secretion of bile. e macroscopic observation scores, mucosal injury index scores, and esophageal inflammation scores were decreased, which presented that ZHG protected the mucosal injury and inflammatory damage; the levels of GAS, MTL, and vasoactive intestinal peptide (VIP) in serum of rats with reflux esophagitis were decreased; the result shows that the ZHG regulates the serum gastrointestinal hormone levels
Summary
Gastroesophageal reflux diseases (GERDs) are the symptoms or complications resulting from the reflux of gastric contents into the esophagus, oral cavity (including larynx), or lung [1]. Proton pump inhibitor is the preferred drug of choice [2, 5] It is the most potent in inhibiting gastric acid secretion and relieving the pain in patients with GERDs, but 20 to 30 percent of patients reported no significant results [6]. Gastroesophageal reflux disease (GERDs) is a common chronic digestive system disease, in which the symptoms of reflux esophagitis (RE) seriously affect the quality of life. We aimed to study the therapeutic effect of Zhujie Hewei granules (ZHG) on reflux esophagitis in model rats. Histopathological changes of the esophagus were observed with hematoxylin-eosin staining
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
